Medical and Pediatric Oncology · 2002 · 23 citations · 6 references
MedicineOncologyPediatricsChemotherapyNeuro-oncologyPediatric OncologyChemotherapy Toxicity ManagementHematologic Malignancy TherapyHematologic ToxicityPediatric ChemotherapyPediatric LeukemiasPediatric Nuclear ImagingAcute Leukemia ChemotherapyAcute Lymphoblastic Leukemia TherapyAcute Lymphoblastic Leukemia TreatmentDelayed NeurotoxicityIntrathecal MethotrexateNeoplastic DiseasePediatric Hematologic Malignancy ChemotherapyRelapsed Leukemia
Methotrexate (MTX) is an essential chemotherapeutic agent for the treatment of neoplastic diseases. It has substantially contributed to the decrease of central nervous system (CNS) and testicular relapses in childhood acute lymphoblastic leukemia (ALL) and thus to the remarkably improved prognosis of this disease. However, intensive MTX-treatment bears considerable risk of acute and delayed toxicity, for example, mucositis, myelosuppression, renal dysfunction, and CNS toxicity. CNS abnormalities occur in a substantial number of patient's either on nuclear magnetic resonance (NMR) imaging alone or with clinical manifestations. These mainly comprise aseptic meningitis, transverse myelopathy, stroke-like syndrome, and acute or chronic encephalopathy Our experience with an adolescent who developed subacute leukencephalopathy after initial intrathecal MTX administration for ALL is instructive.
6
Christine F. Skibola, Martyn T. Smith, Eleanor Kane et al. · Proceedings of the National Academy of Sciences · 1999 · 530 citations · Full text
Joseph L. Wiemels, R. Smith, G. Malcolm Taylor et al. · Proceedings of the National Academy of Sciences · 2001 · 339 citations · Full text
Neurologic Complications of Cancer.
B. Lee Ligon · Neurosurgery · 1996 · 226 citations
Reinin Asato, Yuichi Akiyama, Masatoshi Ito et al. · Cancer · 1992 · 133 citations · Full text